Patient Clusters and Cost Trajectories in Atrial Fibrillation: Evidence from the Swiss Atrial Fibrillation Cohort

Aims Evidence on long-term costs of atrial fibrillation (AF) and associated factors is scarce. As part of the Swiss-AF prospective cohort study we aimed to characterise AF costs and their development over time, and to assess specific patient clusters and their cost trajectories. Methods Swiss-AF enrolled 2,415 patients with variable duration of AF between 2014 and 2017. Patient clusters were identified using hierarchical cluster analysis of baseline characteristics. Ongoing yearly follow-ups include health insurance clinical and claims data. An algorithm was developed to adjudicate costs to AF and related complications. Results Hierarchical analysis identified three patient clusters. "Cardiovascular-dominated" (CV-dominated) patients had the highest proportions of prior myocardial infarction and presence of diabetes. "Heart failure-dominated" (HF-dominated) patients had the highest occurrence of heart failure and permanent AF. "Isolated symptomatic" (IS) patients were younger and had the highest occurrence of paroxysmal AF. A subpopulation of 1,024 Swiss-AF patients with available claims data was followed up for a median [interquartile range] of 3.24 [1.09] years. Average yearly AF-adjudicated costs amounted to CHF 5,679, remaining stable across the observation period. CV-dominated (N = 253 with claims data) and HF-dominated patients (N = 185) depicted similarly high costs across all cost outcomes, the IS (N = 586) patients accrued the lowest costs. Conclusion Our results highlight three well-differentiated patient clusters with specific costs that could be used for stratification in both clinical and economic studies. Patient characteristics associated with adjudicated costs as well as cost trajectories may enable an early understanding of the magnitude of upcoming AF-related healthcare costs.

[1]  J. Piccini,et al.  A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation. , 2019, The American journal of cardiology.

[2]  D. Conen,et al.  Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. , 2019, Journal of the American College of Cardiology.

[3]  S. Johnsen,et al.  Cost of illness of atrial fibrillation: a nationwide study of societal impact , 2017, BMC Health Services Research.

[4]  C. Becker Cost-of-illness studies of atrial fibrillation: methodological considerations , 2014, Expert review of pharmacoeconomics & outcomes research.

[5]  C. Huber,et al.  Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications , 2013, BMC Public Health.

[6]  Albert Hofman,et al.  Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. , 2013, European heart journal.

[7]  Simon Stewart,et al.  Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. , 2013, International journal of cardiology.

[8]  Prashanthan Sanders,et al.  The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. , 2012, Archives of internal medicine.

[9]  Dante Morra,et al.  A review of the cost of atrial fibrillation. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  I. V. Van Gelder,et al.  The cost of illness of atrial fibrillation: a systematic review of the recent literature. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  C. Albert,et al.  Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. , 2011, JAMA.

[12]  J. Stephenson,et al.  Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed , 2009, Current medical research and opinion.

[13]  D. Battleman,et al.  Cost of atrial fibrillation in United States managed care organizations , 2009, Advances in therapy.

[14]  Massimo Santini,et al.  Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. , 2008, European heart journal.

[15]  Peter Lindgren,et al.  Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[17]  J. McMurray,et al.  Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK , 2004, Heart.

[18]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[19]  G. Boriani,et al.  The cost of atrial fibrillation in Italy: a five-year analysis of healthcare expenditure in the general population. From the Italian Survey of Atrial Fibrillation Management (ISAF) study. , 2017, European review for medical and pharmacological sciences.

[20]  B. Chang,et al.  Contemporary Review , 2015 .